Cognition Therapeutics Inc (CGTX): Total Assets
$48.39M
As of 2025-12-31
$38.90M
As of 2026-06-30
-1.4%
3-year compound annual growth
+46.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.39M | +60.1% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $30.23M | -14.0% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $35.16M | -30.3% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $50.42M | -14.7% | 2024-03-26, Balance as of period end |
| 2021-12-31 | $59.14M | +730.7% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $7.12M | n/a | 2022-03-30, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Cognition Therapeutics Inc (CGTX) | 2025-12-31 | $48.39M | +60.1% |
| PharmaCyte Biotech, Inc. (PMCB) | 2026-04-30 | $46.75M | -15.3% |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | $51.22M | -47.6% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| Viskase Holdings, Inc. (VISK) | 2025-12-31 | $42.81M | -9.2% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $59.74M | -41.2% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $61.88M | -36.3% |
| Passage BIO, Inc. (PASG) | 2025-12-31 | $62.28M | -39.2% |
| Elutia Inc. (ELUT) | 2025-12-31 | $62.35M | +72.6% |
Compare CGTX, PMCB, SNTI, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗